BiotechTube

AL001

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Frontotemporal Dementia

Conditions

Frontotemporal Dementia

Trial Timeline

Sep 27, 2019 → Jun 5, 2024

NCT ID
NCT03987295

About AL001

AL001 is a phase 2 stage product being developed by Alector for Frontotemporal Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT03987295. Target conditions include Frontotemporal Dementia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03987295Phase 2Completed
NCT03636204Phase 1Completed

Competing Products

7 competing products in Frontotemporal Dementia

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
41
galantamine hydrobromideJohnson & JohnsonPhase 2
52
memantine hydrochlorideLundbeckPhase 3
74
SyntocinonBrain BiotechPhase 2
44
DNL593 + PlaceboDenali TherapeuticsPhase 1/2
36
PBFT02Passage BioPhase 1/2
33

Other Products from Alector

AL001 + Placebo + Open label - AL001Phase 3
69
LatozinemabPhase 3
69
GSK4527226Phase 2
44
GSK4527226Phase 2
44
AL001 + PlaceboPhase 2
44